Cardiorenal Risk Stratification Pilot Study (CRiSPS): Using FGF-23 as a Risk Stratification Biomarker in Patients with Heart Failure and Chronic Kidney Disease as a Predictor of 1-year Morbidity and Mortality Risk. Here, FGF23 is linked to chronic kidney disease.